(Q33636573)

28 July 2017

1 reference

title

Immunosuppressive and antiproliferative effects of HMG-CoA reductase inhibitors (English)

1 reference

28 July 2017

Katznelson S

1

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 May 1999

1 reference

Transplantation Proceedings

28 July 2017

published in

1 reference

28 July 2017

volume

31

1 reference

28 July 2017

issue

3B Suppl

1 reference

28 July 2017

page(s)

22S-24S

1 reference

Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Hyperlipidemia in renal transplant recipients: natural history and response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Risk factors predicting chronic rejection of renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

The effects of pravastatin on hyperlipidemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Lovastatin treatment of hypercholesterolemia in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Effect of pravastatin on outcomes after cardiac transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

The effect of pravastatin on acute rejection after kidney transplantation--a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Role of mevalonic acid in the regulation of natural killer cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

HMG-CoA reductase inhibitors pravastatin and simvastatin inhibit human B-lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Chemotaxis of the monocyte cell line U937: Dependence on cholesterol and early mevalonate pathway products

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Pravastatin and cyclosporine inhibit platelet-derived growth factor-stimulated vascular smooth muscle cell mitogenesis: an investigation of mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Pravastatin increases survival and inhibits natural killer cell enhancement factor in liver transplanted rats

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

Chronic vascular rejection of the heart and the kidney--have rational treatment options emerged?

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2899%2900098-6

7 January 2021

10.1016/S0041-1345(99)00098-6

Identifiers

DOI

1 reference

28 July 2017

1 reference